Latest Hodgkin's lymphoma Stories
SEATTLE, Aug. 1, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today reported financial results and recent accomplishments for the second quarter of 2012. Recent Company Highlights European Commission grants conditional marketing authorization for Pixuvri as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas ("NHL") Steven E. Benner, M.D., M.H.S. named new...
STAT3 needs to be inhibited to induce immune response in drug-resistant lymphoma Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse. Their...
WHITE PLAINS, N.Y., July 9, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society's (LLS) 2012 Man & Woman of the Year campaign exceeded last year's record-breaking year, raising $18.9 million for blood cancer research and patient services. In its 22nd year more than 800 candidates participated and surpassed last year's fundraising record by $4.2 million. Out of all those candidates, one man, Washington D.C. leukemia survivor Tommy Cleaver, and one woman, St. Louis based...
WHITE PLAINS, N.Y., July 9, 2012 /PRNewswire/ -- Over the past decade, Burlington Coat Factory has raised close to $13 million through its company-wide initiative encouraging its customers to purchase paper balloon icons as a donation to The Leukemia & Lymphoma Society (LLS) to help fund cancer research and patient services, Today, Burlington Coat Factory, LLS's #1 National Corporate Light The Night(®) Walk partner, announced the launch of its 11th year in support of the...
SAN DIEGO, July 9, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announces it has received Investigational Review Board (IRB) approval at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center for a Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of cutaneous T-cell...
A new cancer drug with remarkably few side effects is dramatically improving survival in Hodgkin lymphoma patients who fail other treatments and are nearly out of options. Loyola University Medical Center oncologist Scott E. Smith, MD, PhD presented survival data for the drug, brentuximab vedotin (Adcetris®), at the 17th Congress of the European Hematology Association. Smith is director of Loyola's Hematological Malignancies Research Program. The multi-center study included 102 Hodgkin...
Trial led by St. Jude Children's Research Hospital investigators succeeds in keeping cure rates high for young patients with favorable-risk Hodgkin lymphoma while reducing their chances of serious treatment side effects A multicenter trial showed that nearly half of young patients with early-stage Hodgkin lymphoma can be cured without undergoing either irradiation or intensive chemotherapy that would leave them at risk for second cancers, infertility, heart and other problems later. St....
WHITE PLAINS, N.Y., June 27, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) was deeply saddened to learn of the death of the supremely talented Nora Ephron, from acute myelogenous leukemia (AML). Ephron had been battling myelodysplastic syndrome (MDS), which then progressed to AML. MDS is a group of diseases of the blood and bone marrow, with varying degrees of severity. Sometimes MDS can develop as a result of treatment for a different cancer. MDS is often a...
WHITE PLAINS, N.Y., June 27, 2012 /PRNewswire/ -- Tap your inner superhero and grab your shield: the inaugural Herothon Half Marathon Series Powered by The Leukemia & Lymphoma Society takes flight this winter! The Leukemia & Lymphoma Society (LLS), which has operated the world's biggest and most successful endurance sports training program, Team In Training (TNT), for the past 24 years, is now spreading its wings with this new endurance series of its own. The Herothon...
Trial led by St. Jude Children's Research Hospital investigators succeeds in keeping cure rates high for young patients with favorable-risk Hodgkin lymphoma while reducing their chances of serious treatment side effects MEMPHIS, Tenn., June 26, 2012 /PRNewswire-USNewswire/ -- A multicenter trial showed that nearly half of young patients with early-stage Hodgkin lymphoma can be cured without undergoing either irradiation or intensive chemotherapy that would leave them at risk for...
